OncoMatch/Clinical Trials/NCT04178174
Stereotactic Boost and Short-course Radiation Therapy for Oropharynx Cancer
Is NCT04178174 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies non-drug interventions for head and neck cancer.
This is a randomized clinical trial comparing the outcomes of short-course chemoradiation consisting in stereotactic boost to the gross tumor and de-esclalated chemoradiation to the elective neck in human papilloma associated oropharynx cancer vs. the current standard 7-week course chemoradiation.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Biomarker criteria
Required: HPV positive
Positive for HPV by p16 immunohistochemistry (IHC) or HPV in-situ hybridization (ISH)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: irradiation of the head and neck region
Previous irradiation of the head and neck region
Cannot have received: surgery of the HNC region
Exception: except for incisional or excisional biopsies
Previous surgery of the HNC region (except for incisional or excisional biopsies)
Cannot have received: induction chemotherapy
Prior induction chemotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify